Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRK proto-oncogene, adaptor protein (CRK)
- Target
- CRK
- Molecular classification
- Adapter protein, Signal transduction adapter, Other
01
Overview
CRK proto-oncogene, adaptor protein (CRK) is a member of the adapter protein family and encodes a protein containing src-homology (SH2 and SH3) domains, allowing it to interact with tyrosine-phosphorylated proteins and mediate signal transduction. CRK is involved in key cellular processes such as cell adhesion, migration, spreading, actin dynamics, and phagocytosis, often acting downstream of receptor tyrosine kinases (e.g., c-Met). The protein plays roles in regulating actin cytoskeleton organization and mediating signaling events that affect cell motility and transformation. Aberrant CRK activity is implicated in various cancers and developmental disorders, highlighting its functional importance in cellular signaling
- Other names
- c-CrkCRK2CRK proto-oncogene, adaptor proteinp38v-crk avian sarcoma virus CT10 oncogene homologCrkoFLJ11558
02
Mechanism of action
Inhibition of CRK-mediated signaling pathways (e.g., interference with SH2/SH3 domain interactions), reduction in downstream signaling for cell migration and proliferation (inferred from general adapter protein functions; not an approved drug MOA yet)
03
Biological functions
Signal transductionCell adhesionCell migrationRegulation of actin cytoskeletonPhagocytosisCell motility
04
Disease associations
CancerDevelopmental disorders (e.g., Miller-Dieker lissencephaly syndrome)Sarcoma
05
Safety considerations
Potential risks with targeting adapter proteins broadly as they are involved in many essential signaling pathways; may affect normal cell adhesion, migration, or immune responses (general concern with adapter molecule targeting)
06
Interacting drugs
None clearly established as direct approved drugs; the protein may be involved in targeted research inhibition, but no clinically approved drugs are listed for direct CRK inhibition
07
Biomarkers
Not routinely used as a biomarker for patient selection in clinical practice; expression or phosphorylation status may serve as a research biomarker in cancer biology
Beyond the preview
Go deeper on CRK proto-oncogene, adaptor protein (CRK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRK proto-oncogene, adaptor protein (CRK).